{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:49:26Z","timestamp":1790743766790,"version":"4.1.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Limited antiretrovirals are currently available for the management of multidrug-resistant (MDR) HIV-1 infection. Ibalizumab, a recombinant humanized monoclonal antibody, represents the first novel agent for HIV-1 management in over a decade and is the first monoclonal antibody for the treatment of MDR HIV-1 infection in combination with other forms of antiretroviral therapy in heavily treatment-experienced adults who are failing their current antiretroviral regimen.<\/jats:p>","DOI":"10.1128\/aac.00110-19","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T08:06:08Z","timestamp":1552550768000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":90,"title":["Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection"],"prefix":"10.1128","volume":"63","author":[{"given":"Mario V.","family":"Beccari","sequence":"first","affiliation":[{"name":"State University of New York Upstate University Hospital, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-6366","authenticated-orcid":false,"given":"Bryan T.","family":"Mogle","sequence":"additional","affiliation":[{"name":"State University of New York Upstate University Hospital, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Sidman","sequence":"additional","affiliation":[{"name":"State University of New York Upstate University Hospital, Syracuse, New York, USA"},{"name":"State University of New York Upstate Medical University, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri A.","family":"Mastro","sequence":"additional","affiliation":[{"name":"Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Asiago-Reddy","sequence":"additional","affiliation":[{"name":"State University of New York Upstate Medical University, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-096X","authenticated-orcid":false,"given":"Wesley D.","family":"Kufel","sequence":"additional","affiliation":[{"name":"State University of New York Upstate University Hospital, Syracuse, New York, USA"},{"name":"State University of New York Upstate Medical University, Syracuse, New York, USA"},{"name":"Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02323"},{"key":"e_1_3_2_3_2","volume-title":"Trogarzo (ibalizumab-uiyk): new orphan drug approval","author":"OptumRx","year":"2018","unstructured":"OptumRx. 2018. Trogarzo (ibalizumab-uiyk): new orphan drug approval. OptumRx, Irvine, CA."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920108786786358"},{"key":"e_1_3_2_6_2","volume-title":"Trogarzo (ibalizumab-uiyk): highlights of prescribing information","author":"TaiMed Biologics","year":"2018","unstructured":"TaiMed Biologics. 2018. Trogarzo (ibalizumab-uiyk): highlights of prescribing information. TaiMed Biologics, Irvine, CA."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.628610"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00453-10"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00942-08"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R112.406272"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/380802"},{"key":"e_1_3_2_12_2","volume-title":"Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy versus IV administration, abstr 438.","author":"Lin H-H","year":"2017","unstructured":"Lin H-H, Lee SS-J, Wang N-C, Lai Y, Kuo K-L, Weinheimer S, Lewis S. 2017. Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy versus IV administration, abstr 438. Proc Conf Retrovir Opportunistic Infect. International Antiviral Society-USA, San Francisco, CA."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4734"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2000.4975"},{"key":"e_1_3_2_15_2","volume-title":"IDWeek 2018","author":"Kumar P","year":"2018","unstructured":"Kumar P, Weinheimer S, Cohen Z, Marsolais C, Kuo K-L, Lewis S. 2018. Pharmacokinetic profile of ibalizumab from a phase 3 trial, abstr 544. IDWeek 2018. Infectious Diseases Society of America, Arlington, VA."},{"key":"e_1_3_2_16_2","volume-title":"oceedings of the Conference on Retroviruses and Opportunistic Infections 2018.","author":"Weinheimer S","year":"2018","unstructured":"Weinheimer S, Marsolais C, Cohen Z, Lewis S. 2018. Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals, abstr 561. Proceedings of the Conference on Retroviruses and Opportunistic Infections 2018. International Antiviral Society\u2013USA, San Francisco, CA."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182732746"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2004.01.005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0029-x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.03.255"},{"key":"e_1_3_2_21_2","volume-title":"TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks","author":"Norris D","year":"2006","unstructured":"Norris D, Morales J, Godofsky E, Garcia F, Hardwicke R, Lewis S. 2006. TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks, abstr THLB0218. XVI International AIDS Conference\/International AIDS Society, Geneva, Switzerland."},{"key":"e_1_3_2_22_2","volume-title":"Proc 51st Intersci Conf Antimicrob Agents Chemother","author":"Khanlou H","year":"2011","unstructured":"Khanlou H, Gathe J, Schrader S, Towner W, Weinheimer S, Lewis S. 2011. Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1-infected patients: a phase 2b study, abstr H2-804. Proc 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx162.093"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02237-10"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.09.010"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00761-05"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/481314"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/v5020595"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01954-06"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00925-09"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821197116"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001119"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2014.0235"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000218"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.06.170"},{"key":"e_1_3_2_36_2","volume-title":"Proc 54th Intersci Conf Antimicrob Agents Chemother","author":"Ernst JK","year":"2014","unstructured":"Ernst JK, Keefer M, Lalezari J, Goepfert P, Schrader S, Devente J, Vasan S, Padte NN, Kuo K-L, Weinheimer S, Lewis S. 2014. Subcutaneous ibalizumab in at-risk healthy subjects, abstr H-995. Proc 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_37_2","first-page":"127","article-title":"Investigational antiretroviral drugs: what is coming down the pipeline","volume":"25","author":"Gulick RM","year":"2018","unstructured":"Gulick RM. 2018. Investigational antiretroviral drugs: what is coming down the pipeline. Top Antivir Med 25:127\u2013132.","journal-title":"Top Antivir Med"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000469"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00110-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00110-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:30:11Z","timestamp":1645461011000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00110-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1128\/AAC.00110-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00110-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"2019-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00110-19"}}